ES2572330A2 - Combinacion de al menos dos agentes antivirales de accion directa (aad) para su uso en el tratamiento del vhc - Google Patents

Combinacion de al menos dos agentes antivirales de accion directa (aad) para su uso en el tratamiento del vhc

Info

Publication number
ES2572330A2
ES2572330A2 ES201431520A ES201431520A ES2572330A2 ES 2572330 A2 ES2572330 A2 ES 2572330A2 ES 201431520 A ES201431520 A ES 201431520A ES 201431520 A ES201431520 A ES 201431520A ES 2572330 A2 ES2572330 A2 ES 2572330A2
Authority
ES
Spain
Prior art keywords
hcv
bis
treatment
antiviral agents
ada
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201431520A
Other languages
English (en)
Other versions
ES2572330R1 (es
ES2572330B1 (es
Inventor
Barry M Bernstein
Rajeev M Menon
Amit Khatri
Sven Mensing
Sandeep Dutta
Daniel E Cohen
Thomas J Podsadecki
Scott C Brun
Walid M Awni
Emily O Dumas
Cheri E Klein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of ES2572330A2 publication Critical patent/ES2572330A2/es
Publication of ES2572330R1 publication Critical patent/ES2572330R1/es
Application granted granted Critical
Publication of ES2572330B1 publication Critical patent/ES2572330B1/es
Withdrawn - After Issue legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Combinación de al menos dos agentes antivirales de acción directa (AAD) para su uso en el tratamiento del VHC. La presente invención presenta combinaciones de agentes antivirales de acción directa (AAD) para uso en terapias sin interferón ni ribavirina en el tratamiento de VHC, durante un tiempo de tratamiento corto, tal como no más de 12 semanas. Los al menos dos AAD comprenden al menos un inhibidor de proteasa del VHC que es un agente terapéutico 1 o Compuesto 1, conocido como (2R, 6S, l3aS, l4aR, l6aS, Z)-N-(ciclopropilsulfonil)-6-(5- metilpirazin-2-carboxamido)-5,16-dioxo-2-(fenantridin-6-iloxi)-1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 13a, 14, 14a, 15, 16, 16a-hexadecahidrociclopropa [e] pirrolo [1, 2-a] [1,4] diazaciclopentadecin-14a-carboxamida, y al menos un inhibidor de NS5A que es un agente terapéutico 4 o Compuesto 4, conocido como dimetil (2S, 2'S)-1,1'-((2S, 2'S)-2,2'-4,4'-((2S, 5S)-1-(4-terc-butilfenil) pirrolidin-2,5, diil) bis (4,1-fenilen))bis (azanediil)bis(oxometilen)bis(pirrolidin-2,1-diil)bis(3-metil-1-oxobutano-2,1-diil)dicarbamato.
ES201431520A 2011-10-21 2012-10-19 Combinación de al menos dos agentes antivirales de acción directa (aad) para su uso en el tratamiento del vhc Withdrawn - After Issue ES2572330B1 (es)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US201161055036P 2011-10-21 2011-10-21
US61/55036 2011-10-21
US201161056217P 2011-11-21 2011-11-21
US61/56217 2011-11-21
US201261058719P 2012-01-17 2012-01-17
US61/58719 2012-01-17
US201261060046P 2012-02-17 2012-02-17
US61/60046 2012-02-17
US201261061988P 2012-04-03 2012-04-03
US61/61988 2012-04-03
US201261065625P 2012-06-06 2012-06-06
US61/65625 2012-06-06
US201261071179P 2012-10-10 2012-10-10
US61/71179 2012-10-10

Publications (3)

Publication Number Publication Date
ES2572330A2 true ES2572330A2 (es) 2016-05-31
ES2572330R1 ES2572330R1 (es) 2016-11-03
ES2572330B1 ES2572330B1 (es) 2017-08-24

Family

ID=52465028

Family Applications (3)

Application Number Title Priority Date Filing Date
ES201490005A Expired - Fee Related ES2529144B1 (es) 2011-10-21 2012-10-19 Combinación de aad para uso en el tratamiento del vhc
ES201431520A Withdrawn - After Issue ES2572330B1 (es) 2011-10-21 2012-10-19 Combinación de al menos dos agentes antivirales de acción directa (aad) para su uso en el tratamiento del vhc
ES201431521A Withdrawn - After Issue ES2572355B1 (es) 2011-10-21 2012-10-19 Combinación de aad para uso en el tratamiento del vhc

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES201490005A Expired - Fee Related ES2529144B1 (es) 2011-10-21 2012-10-19 Combinación de aad para uso en el tratamiento del vhc

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES201431521A Withdrawn - After Issue ES2572355B1 (es) 2011-10-21 2012-10-19 Combinación de aad para uso en el tratamiento del vhc

Country Status (1)

Country Link
ES (3) ES2529144B1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA020031B1 (ru) * 2009-06-11 2014-08-29 Эббви Бахамаз Лтд. Противовирусные соединения
NZ602288A (en) * 2010-03-10 2014-02-28 Abbvie Bahamas Ltd Solid compositions comprising amorphous (2r,6s,13as,14ar,16as,z)-n-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide

Also Published As

Publication number Publication date
ES2572330R1 (es) 2016-11-03
ES2529144R1 (es) 2015-03-10
ES2572355R1 (es) 2016-11-03
ES2529144B1 (es) 2015-10-26
ES2572355B1 (es) 2017-08-24
ES2572355A2 (es) 2016-05-31
ES2572330B1 (es) 2017-08-24
ES2529144A2 (es) 2015-02-17

Similar Documents

Publication Publication Date Title
ES2572328A2 (es) Combinacion de al menos dos agentes antivirales de accion directa y ribavirina pero no interferon, para su uso en el tratamiento del vhc
DOP2011000087A (es) Compuestos eficaces para inhibir la replicación del virus de la hepatitis c("HCV")
NZ599284A (en) Combinations of a specific hcv ns5a inhibitor and an hcv ns3 protease inhibitor
UY30437A1 (es) Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
UY30392A1 (es) Compuestos de oximilo macrociclico inhibidores de proteasa de hepatitis c
UA116616C2 (uk) Інгібітори hcv серинової протеази, отримані з макроциклічного проліну
BRPI0508085A (pt) compostos de enxofre como inibidores da ns3 serina protease do vìrus da hepatite c
EA200970805A1 (ru) Ингибиторы серинпротеаз для лечения hcv инфекций
MX2009009176A (es) Inhibidores de serina-proteasas.
AR084393A1 (es) Metodos para tratar el virus de la hepatitis c, composicion, uso, combinacion, kit y uno o mas compuestos anti vhc
EA201400358A1 (ru) Замещенные n-[1-циано-2-(фенил)этил]-2-азабицикло[2.2.1]гептан-3-карбоксамидные ингибиторы катепсина с
ECSP088258A (es) Inhibidores de serina proteasas
MX2010006210A (es) Inhibidores de serina proteasa de hcv de tripeptido fluorado.
PA8603801A1 (es) Derivados de la quinazolina
EA200900969A1 (ru) Макроциклические ингибиторы протеазы гепатита с
ATE512954T1 (de) Als inhibitoren des hepatitis-c-virus (hcv) geeignete n-phenyldioxohydropyrimidine
ATE513844T1 (de) Acylsulfonamidverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
AR063942A1 (es) Compuestos de oximilo aciclico inhibidores de proteasa del virus de hepatitis c
ECSP066795A (es) Compuestos novedosos como inhibidores de ns3 serina proteasa del virus de hepatitis c
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
ECSP045191A (es) "nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c"
ECSP066794A (es) Nuevos compuestos como inhibidores de serina proteasa ns3 del virus de la hepatitis c
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
CL2012001230A1 (es) Compuestos derivados de biciclos, inhibidores de la proteina ns5a; composicion farmaceutica que los comprende; uso en el tratamiento de la hepatitis c.
WO2005077969A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2572330

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20170824

FA2A Application withdrawn

Effective date: 20180212